GSK says ‘nicely positioned’ to reply to US tariff threats, CFO Information, ETCFO
London, Apr 30, 2025 -British drugmaker GlaxoSmithKline mentioned Wednesday it’s “nicely positioned” to reply to US President Donald Trump’s potential tariffs on prescribed drugs and maintained its 2025 outlook.
The US launched an investigation into pharmaceutical imports in April, opening the door to potential tariffs on the sector beforehand spared from Trump’s sweeping levies on buying and selling companions.
“The corporate is nicely positioned to reply to the potential monetary affect of sector-specific tariffs, ought to they be carried out, with mitigation choices recognized,” GSK mentioned in its first-quarter earnings assertion.
GSK additionally introduced that revenue after tax jumped over 50 p.c within the first quarter to £1.62 billion ($2.17 billion).
Income rose two p.c to £7.5 billion.
The US remained by far its largest market, representing round half of its income, whereas Europe accounted for 23 p.c.
Chief govt Emma Walmsley welcomed the corporate’s “sturdy progress,” particularly sturdy gross sales of its “Specialty Medicines,” which incorporates medicine for HIV, most cancers and respiratory illnesses.
ajb/lth
